The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1118
November 12, 2001
View Complete Issue         Table of Contents 2019 
Issue 1118
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Cardiovascular Safety of Cox-2 Inhibitors
November 12, 2001 (Issue: 1118)
Related Articles Since Publication Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex), both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1118
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.